Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 652 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastasis to Lung Clear all
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer
Interventions
Docetaxel, Vandetanib
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Lenvatinib, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
28
States / cities
Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Interventions
AVID100 IV
Drug
Lead sponsor
Formation Biologics
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Brain Cancer
Interventions
Tarceva (Erlotinib hydrochloride), Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced May 22, 2026, 3:47 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
Interventions
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Kidney Cancer, Lung Cancer
Interventions
interleukin-4 PE38KDEL cytotoxin
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced May 22, 2026, 3:47 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
COVID Prevention Program (CPP)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
COVID-19
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Orange, California • Alexandria, Louisiana • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions
cabozantinib
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
LY3023414, Necitumumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Chandler, Arizona • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions
SLC-391, pembrolizumab
Drug · Biological
Lead sponsor
SignalChem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 22, 2026, 3:47 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced May 22, 2026, 3:47 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Behavioral Dietary Intervention, Text Message-Based Navigation Intervention, Internet-Based Intervention, Dietary Counseling and Surveillance, Stereotactic Radiosurgery, Biospecimen Collection, Magnetic Resonance Imaging, Neurocognitive Assessment, Questionnaire Administration, Interview
Behavioral · Other · Radiation + 1 more
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions
Ionizing radiation (IR) therapy, Ionizing radiation (IR)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Cancer, Cancer, Lung
Interventions
CPO301
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced May 22, 2026, 3:47 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF9001, KEYTRUDA® (pembrolizumab)
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced May 22, 2026, 3:47 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
16
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced May 22, 2026, 3:47 AM EDT